Key facts
- Novo Nordisk is considering upgrading its New York listing to enhance its profile in the US.
- CEO Mike Doustdar stated that a direct listing on the NYSE is being considered to replace American depositary receipts.
- Doustdar believes weight-loss pills could capture 50% of the global obesity drug market by 2030.
Novo Nordisk is open to the idea of upgrading its listing on the New York Stock Exchange as part of efforts to raise the Danish weight-loss drugmaker's profile in the country, according to CEO Mike Doustdar. Doustdar told the Financial Times that he sees "some advantages" with the company considering a direct listing on the NYSE, which would replace the American depositary receipts that currently provide U.S. investors access to the stock. The comments come as Novo Nordisk's CEO also projected that weight-loss pills could capture half of the global obesity drug market by 2030.